ProCE Banner Activity

TRANSCEND CLL 004: Phase I/II Trial of Lisocabtagene Maraleucel for Relapsed/Refractory CLL/SLL

Conference Coverage
Slideset

In an updated analysis of the phase I/II TRANSCEND CLL 004 trial evaluating lisocabtagene maraleucel for patients with R/R CLL/SLL, the CR/CRi rate was 18%.

Released: June 12, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis